NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

NEUROTECH INTERNATIONAL LIMITED (NTI)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of NTI: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000NTI9
Address: Suite 5 CPC 145 Stirling Highway Nedlands WA 6009
Tel:  +61 8 9389 3130Fax: +61 (0)8 9321 5932

Date first listed: 04/11/2016
Company Secretary: Erlyn Dale
Sector: Health Care Equipment & Services 
Activities: Development of wearable neurotechnology devices to assist with neurological conditions such as autism

News & Events

Expand this box to read and print

The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding a capital raise.

28/10/2022

The company releases an Investor Presentation.

28/10/2022

The company releases a notice of proposed issue of securities.

28/10/2022

Single tranche share Placement conducted following further strong clinical trial results at 20 weeks for NTI164 in children with Autism Spectrum Disorder. Binding commitments for a $9.0 million Placement with support from existing and new institutional, professional and sophisticated Australian and overseas investors. Capital raised fully funds multiple Phase I/II clinical trials in PANDAS/PANS and cerebral palsy, a large Phase II/III trial in ASD and various US FDA initiatives.

28/10/2022

The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a capital raise.

27/10/2022

The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder.

08/07/2022

93% of patients showed symptom improvement relating to the severity of illness after 28 days of daily treatment with NTI164. 64% of patients had a global improvement of "much improved'". 29% of patients had a global improvement of "minimally improved". 7% of patients had "no change". Two patients recorded a Marked Therapeutic Index Score of 2 = vast improvement meaning: complete or near remission of all symptoms. Ten patients recorded a Moderate Therapeutic Index Score of 5 & 6 = representing "Decided improvement" "“ Partial remission of symptoms. The average rating for the severity of illness at baseline was 4.4. This was reduced to 3.6 after 28 days of NTI164 treatment. NTI164 was well-tolerated "“ No serious adverse events were recorded across all doses (5, 10, 15 and 20 mg/kg). No changes were noted in blood analysis or liver function tests. The study has been granted HREC approval to continue for a further 54 weeks due to the positive therapeutic effects of NTI164 combined with feedback from parents and clinicians and their recent request for no "washout" period. Safety and efficacy assessments will continue. ï‚· The Company is in discussions with the US FDA regarding a pre-IND application scheduled for 2022. ï‚· Existing prescribed medications for the treatment of symptoms associated with ASD have untoward side effects including weight gain, sedation and hormonal imbalance. Given that NTI164 was welltolerated without weight gain or sedation, NTI164 shows promise compared to these treatments . Recently completed and published paediatric ASD studies utilising CBD and/or THC do not show any statistical efficacy and had minimal effects after three plus months and (with a THC component) had "˜sedation' as a significant side effect2,3. NTI164 measures favourably when compared to these treatments. The results open up opportunities for a potential treatment pathways outside of ASD including a wide range of neurological disorders such as Attention Deficit Hyperactivity Disorder ("ADHD"), Multiple Sclerosis, Motor Neuron Disease, Rett's Syndrome, Concussion and Cerebral Palsy. Conference Call with CEO, Dr Alexandra Andrews to be held at 11am WST today "“ details to follow.

08/07/2022

The company wishes that its voluntary suspension remain in place until such time as the announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder is released to the market, or until the commmencement of trade on 8 July 2022.

07/07/2022

The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder.

06/07/2022

The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by NTI of an announcement regarding further results of the in-vitro cell studies of its cannabis strains.

30/11/2020

DOLCE/NTI leads indicate significant increased potency in repairing brain cells when compared to CBD alone. These results have been achieved using 1/5th the dose of CBD alone. DOLCE/NTI leads found to exhibit novel modes of action critical in the treatment and management of Alzheimer's, Huntington's Disease, Multiple Sclerosis and other neurological disorders. DOLCE/NTI leads contains minimal THC (<0.3%) which may result in less onerous regulatory pathway towards commercialisation. Final In-vitro results expected next month. Conference call to be held at 11am AWST today.

30/11/2020

The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding further results of the in-vitro cell studies of its cannabis strains.

27/11/2020

The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following receipt of a response to ASX's Price and Volume Query.

01/05/2020

The company issues a Response to ASX Price and Volume Query.

01/05/2020

The company lodges its Quarterly Report and Appendix 4C.

29/04/2020

The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Monday 4th May 2020.

28/04/2020

The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Tuesday 28th April 2020.

20/04/2020

The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a response to a price query.

14/04/2020

The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by the Company of an announcement regarding a capital raising.

16/10/2017

The company has successfully completed a well oversubscribed A$4 million placement of new shares to drive the company's ongoing commercialisation of the Mente Autism device.

16/10/2017

The securities of Neurotech International Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement.

12/10/2017

listed entity carried for record purposes only

04/11/2016

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    29/01/2024Thomas Duthy340,000$0.091$30,820
    02/08/2022Gerald Quigley277,777$0.090$25,000
    14/07/2021Krista Bates180,000$0.056$10,044
    14/07/2021Allan Cripps180,000$0.056$10,018
    22/06/2021Brian Leedman933,589$0.054$49,962

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Mark DaviesNon Exec Chairman, Independent Director16/04/2019
    Alexandra AndrewsCOO08/03/2022
    Richard SmallCFO, COO04/11/2016
    Winton WilleseeIndependent Director16/04/2019
    Gerald QuigleyNon Exec Director07/07/2022
    Thomas DuthyExecutive Director01/09/2022

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Allan CrippsNon Exec Director19/05/202121/12/2022
    Brian LeedmanNon Exec Chairman19/10/202016/08/2022
    Krista BatesNon Exec Director05/04/202116/08/2022
    Peter GriffithsExecutive04/11/201621/10/2020
    David CantorNon Exec Director04/07/201819/10/2020
    Peter O'ConnorChairman04/11/201616/04/2019
    Neale FongNon Exec Director03/10/201816/04/2019
    Simon TrevisanNon Exec Director04/11/201616/04/2019
    Cheryl TanNon Exec Director04/11/201602/12/2018
    Wolfgang StorfManaging Director, CEO04/11/201626/11/2018
    Adrian TrevisanNon Exec Director15/01/201628/06/2018

    Date of first appointment, title may have changed.